BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Talar-Wojnarowska R, Gasiorowska A, Smolarz B, Romanowicz-Makowska H, Kulig A, Malecka-Panas E. Clinical significance of interleukin-6 (IL-6) gene polymorphism and IL-6 serum level in pancreatic adenocarcinoma and chronic pancreatitis. Dig Dis Sci. 2009;54:683-689. [PMID: 18661238 DOI: 10.1007/s10620-008-0390-z] [Cited by in Crossref: 62] [Cited by in F6Publishing: 60] [Article Influence: 4.8] [Reference Citation Analysis]
Number Citing Articles
1 Harun-Or-Roshid M, Ali MB, Jesmin, Mollah MNH. Statistical meta-analysis to investigate the association between the Interleukin-6 (IL-6) gene polymorphisms and cancer risk. PLoS One 2021;16:e0247055. [PMID: 33684135 DOI: 10.1371/journal.pone.0247055] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chen J, Huang X. Interleukin-6 Promotes Carcinogenesis Through Multiple Signal Pathways: Comment on: Clinical Significance of Interleukin-6 Gene Polymorphism and IL-6 Serum Level in Pancreatic Adenocarcinoma and Chronic Pancreatitis. Dig Dis Sci 2009;54:1373-4. [DOI: 10.1007/s10620-009-0794-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
3 Farajzadeh Valilou S, Keshavarz-fathi M, Silvestris N, Argentiero A, Rezaei N. The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer. Cytokine & Growth Factor Reviews 2018;39:46-61. [DOI: 10.1016/j.cytogfr.2018.01.007] [Cited by in Crossref: 45] [Cited by in F6Publishing: 47] [Article Influence: 15.0] [Reference Citation Analysis]
4 Kaanane H, Senhaji N, Berradi H, Benchakroun N, Benider A, Karkouri M, El Attar H, Igot Casa, Khyatti M, Nadifi S. Association of Variants in IL6-Related Genes with Lung Cancer Risk in Moroccan Population. Lung 2019;197:601-8. [DOI: 10.1007/s00408-019-00261-0] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
5 Kim HW, Lee JC, Paik KH, Kang J, Kim J, Hwang JH. Serum interleukin-6 is associated with pancreatic ductal adenocarcinoma progression pattern. Medicine (Baltimore). 2017;96:e5926. [PMID: 28151872 DOI: 10.1097/MD.0000000000005926] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
6 Litman-zawadzka A, Łukaszewicz-zając M, Mroczko B. Novel potential biomarkers for pancreatic cancer – A systematic review. Advances in Medical Sciences 2019;64:252-7. [DOI: 10.1016/j.advms.2019.02.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Ling S, Feng T, Jia K, Tian Y, Li Y. Inflammation to cancer: The molecular biology in the pancreas (Review). Oncol Lett 2014;7:1747-54. [PMID: 24932227 DOI: 10.3892/ol.2014.2003] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
8 Taniguchi K, Karin M. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer. Seminars in Immunology. 2014;26:54-74. [PMID: 24552665 DOI: 10.1016/j.smim.2014.01.001] [Cited by in Crossref: 319] [Cited by in F6Publishing: 315] [Article Influence: 45.6] [Reference Citation Analysis]
9 Banday MZ, Balkhi HM, Sameer AS, Chowdri NA, Haq E. Strong association of interleukin-6 −174G/C promoter single nucleotide polymorphism with a decreased risk of colorectal cancer in ethnic Kashmiri population: A case control study. Tumour Biol 2017;39:101042831769594. [DOI: 10.1177/1010428317695940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
10 Śliwińska-mossoń M, Milnerowicz H, Jabłonowska M, Milnerowicz S, Nabzdyk S, Rabczyński J. The effect of smoking on expression of IL-6 and antioxidants in pancreatic fluids and tissues in patients with chronic pancreatitis. Pancreatology 2012;12:295-304. [DOI: 10.1016/j.pan.2012.04.007] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
11 Gomes Dos Santos A, Watanabe EH, Ferreira DT, Oliveira J, Nakanishi ÉS, Oliveira CS, Bocchi E, Novaes CTG, Cruz F, Carvalho NB, Sato PK, Yamashiro-Kanashiro EH, Pontillo A, de Freitas VLT, Onuchic LF, Shikanai-Yasuda MA. A Specific IL6 Polymorphic Genotype Modulates the Risk of Trypanosoma cruzi Parasitemia While IL18, IL17A, and IL1B Variant Profiles and HIV Infection Protect Against Cardiomyopathy in Chagas Disease. Front Immunol 2020;11:521409. [PMID: 33193300 DOI: 10.3389/fimmu.2020.521409] [Reference Citation Analysis]
12 Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Furuse J, Inagaki M, Higashi S, Kato H, Terao K, Ochiai A. Serum levels of IL-6 and IL-1β can predict the efficacy of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 2013;108:2063-2069. [PMID: 23591198 DOI: 10.1038/bjc.2013.174] [Cited by in Crossref: 89] [Cited by in F6Publishing: 84] [Article Influence: 11.1] [Reference Citation Analysis]
13 da Costa MZ, Guarita DR, Ono-Nita SK, Paranaguá-Vezozzo DC, Felga GE, Pedroso MR, de Souza MM, Nasser PD, Ferreira Cda S, Carrilho FJ. Genetic risk for alcoholic chronic pancreatitis. Int J Environ Res Public Health 2011;8:2747-57. [PMID: 21845156 DOI: 10.3390/ijerph8072747] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
14 Hansen M, Nielsen AR, Vilsbøll T, Lund A, Krarup T, Knop FK, Vestergaard H. Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes. Pancreas. 2012;41:1316-1318. [PMID: 22647735 DOI: 10.1097/mpa.0b013e31824d9b93] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
15 Pop VV, Seicean A, Lupan I, Samasca G, Burz CC. IL-6 roles - Molecular pathway and clinical implication in pancreatic cancer - A systemic review. Immunol Lett. 2017;181:45-50. [PMID: 27876525 DOI: 10.1016/j.imlet.2016.11.010] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
16 Mrazek AA, Porro LJ, Bhatia V, Falzon M, Spratt H, Zhou J, Chao C, Hellmich MR. Apigenin inhibits pancreatic stellate cell activity in pancreatitis. J Surg Res. 2015;196:8-16. [PMID: 25799526 DOI: 10.1016/j.jss.2015.02.032] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
17 Ghanavat M, Ebrahimi M, Rafieemehr H, Maniati M, Behzad MM, Shahrabi S. Thrombocytopenia in solid tumors: Prognostic significance. Oncol Rev 2019;13:413. [PMID: 31205603 DOI: 10.4081/oncol.2019.413] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
18 Sharma V, Aggarwal A, Jacob J, Sahni D. Myeloid-derived suppressor cells: Bridging the gap between inflammation and pancreatic adenocarcinoma. Scand J Immunol 2021;93:e13021. [PMID: 33455004 DOI: 10.1111/sji.13021] [Reference Citation Analysis]
19 Monroy CM, Cortes AC, Lopez MS, D'Amelio AM Jr, Etzel CJ, Younes A, Strom SS, El-Zein RA. Hodgkin disease risk: role of genetic polymorphisms and gene-gene interactions in inflammation pathway genes. Mol Carcinog 2011;50:36-46. [PMID: 21061265 DOI: 10.1002/mc.20688] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
20 Mroczko B, Groblewska M, Gryko M, Kedra B, Szmitkowski M. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis. J Clin Lab Anal. 2010;24:256-261. [PMID: 20626020 DOI: 10.1002/jcla.20395] [Cited by in Crossref: 70] [Cited by in F6Publishing: 63] [Article Influence: 6.4] [Reference Citation Analysis]
21 Gomes M, Coelho A, Araújo A, Azevedo A, Teixeira AL, Catarino R, Medeiros R. IL-6 polymorphism in non-small cell lung cancer: a prognostic value? Tumour Biol 2015;36:3679-84. [PMID: 25566963 DOI: 10.1007/s13277-014-3006-6] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
22 Cruz-Monserrate Z, Gumpper K, Pita V, Hart PA, Forsmark C, Whitcomb DC, Yadav D, Waldron RT, Pandol S, Steen H, Anani V, Kanwar N, Vege SS, Appana S, Li L, Serrano J, Rinaudo JAS, Topazian M, Conwell DL; Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer. Biomarkers of Chronic Pancreatitis: A systematic literature review. Pancreatology 2021;21:323-33. [PMID: 33558189 DOI: 10.1016/j.pan.2021.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Zhou L, Zheng Y, Tian T, Liu K, Wang M, Lin S, Deng Y, Dai C, Xu P, Hao Q, Kang H, Dai Z. Associations of interleukin-6 gene polymorphisms with cancer risk: Evidence based on 49,408 cancer cases and 61,790 controls. Gene 2018;670:136-47. [PMID: 29842912 DOI: 10.1016/j.gene.2018.05.104] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 5.3] [Reference Citation Analysis]
24 Wörmann SM, Diakopoulos KN, Lesina M, Algül H. The immune network in pancreatic cancer development and progression. Oncogene 2014;33:2956-67. [PMID: 23851493 DOI: 10.1038/onc.2013.257] [Cited by in Crossref: 106] [Cited by in F6Publishing: 100] [Article Influence: 13.3] [Reference Citation Analysis]
25 Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, Corbo V, Oni TE, Hearn SA, Lee EJ, Chio II, Hwang CI, Tiriac H, Baker LA, Engle DD, Feig C, Kultti A, Egeblad M, Fearon DT, Crawford JM, Clevers H, Park Y, Tuveson DA. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med 2017;214:579-96. [PMID: 28232471 DOI: 10.1084/jem.20162024] [Cited by in Crossref: 678] [Cited by in F6Publishing: 636] [Article Influence: 169.5] [Reference Citation Analysis]
26 Śliwińska-Mossoń M, Milnerowicz S, Milnerowicz H. Diabetes mellitus secondary to pancreatic diseases (type 3c): The effect of smoking on the exocrine-endocrine interactions of the pancreas. Diab Vasc Dis Res 2018;15:243-59. [PMID: 29558826 DOI: 10.1177/1479164118764062] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
27 Karaman K, Bostanci EB, Aksoy E, Kurt M, Celep B, Ulas M, Dalgic T, Surmelioglu A, Hayran M, Akoglu M. The predictive value of mean platelet volume in differential diagnosis of non-functional pancreatic neuroendocrine tumors from pancreatic adenocarcinomas. Eur J Intern Med. 2011;22:e95-e98. [PMID: 22075321 DOI: 10.1016/j.ejim.2011.04.005] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
28 Lesina M, Wörmann SM, Neuhöfer P, Song L, Algül H. Interleukin-6 in inflammatory and malignant diseases of the pancreas. Seminars in Immunology 2014;26:80-7. [DOI: 10.1016/j.smim.2014.01.002] [Cited by in Crossref: 65] [Cited by in F6Publishing: 68] [Article Influence: 9.3] [Reference Citation Analysis]
29 Xu B, Niu XB, Wang ZD, Cheng W, Tong N, Mi YY, Min ZC, Tao J, Li PC, Zhang W, Wu HF, Zhang ZD, Wang ZJ, Hua LX, Feng NH, Wang XR. IL-6 -174G>C polymorphism and cancer risk: a meta-analysis involving 29,377 cases and 37,739 controls. Mol Biol Rep 2011;38:2589-96. [PMID: 21104146 DOI: 10.1007/s11033-010-0399-1] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
30 Mayr M, Schmid RM. Pancreatic cancer and depression: myth and truth. BMC Cancer 2010;10:569. [PMID: 20961421 DOI: 10.1186/1471-2407-10-569] [Cited by in Crossref: 34] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
31 van Duijneveldt G, Griffin MDW, Putoczki TL. Emerging roles for the IL-6 family of cytokines in pancreatic cancer. Clin Sci (Lond) 2020;134:2091-115. [PMID: 32808663 DOI: 10.1042/CS20191211] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
32 Yako YY, Brand M, Smith M, Kruger D. Inflammatory cytokines and angiogenic factors as potential biomarkers in South African pancreatic ductal adenocarcinoma patients: A preliminary report. Pancreatology 2017;17:438-44. [PMID: 28377069 DOI: 10.1016/j.pan.2017.03.003] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
33 Yako YY, Kruger D, Smith M, Brand M. Cytokines as Biomarkers of Pancreatic Ductal Adenocarcinoma: A Systematic Review. PLoS One. 2016;11:e0154016. [PMID: 27170998 DOI: 10.1371/journal.pone.0154016] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 7.4] [Reference Citation Analysis]
34 Palmquist C, Dehlendorff C, Calatayud D, Hansen CP, Hasselby JP, Johansen JS. Prediction of Unresectability and Prognosis in Patients Undergoing Surgery on Suspicion of Pancreatic Cancer Using Carbohydrate Antigen 19-9, Interleukin 6, and YKL-40. Pancreas 2020;49:53-61. [PMID: 31856080 DOI: 10.1097/MPA.0000000000001466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
35 罗妍, 陈晓, 徐向升, 韩根成, 张晓丹, 蒋兴伟, 邢陈, 于佳卉, 周平. 胰腺癌放疗中炎性因子在胃、十二指肠放射性损伤中的变化及临床意义. 世界华人消化杂志 2015; 23(21): 3374-3383 [DOI: 10.11569/wcjd.v23.i21.3374] [Reference Citation Analysis]
36 Fiorino S, Lorenzini S, Masetti M, Deleonardi G, Grondona AG, Silvestri T, Chili E, Del Prete P, Bacchi-Reggiani L, Cuppini A. Hepatitis B and C virus infections as possible risk factor for pancreatic adenocarcinoma. Med Hypotheses. 2012;79:678-697. [PMID: 22959312 DOI: 10.1016/j.mehy.2012.08.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
37 Ramsey ML, Talbert E, Ahn D, Bekaii-Saab T, Badi N, Bloomston PM, Conwell DL, Cruz-Monserrate Z, Dillhoff M, Farren MR, Hinton A, Krishna SG, Lesinski GB, Mace T, Manilchuk A, Noonan A, Pawlik TM, Rajasekera PV, Schmidt C, Guttridge D, Hart PA. Circulating interleukin-6 is associated with disease progression, but not cachexia in pancreatic cancer. Pancreatology 2019;19:80-7. [PMID: 30497874 DOI: 10.1016/j.pan.2018.11.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
38 Komar HM, Serpa G, Kerscher C, Schwoegl E, Mace TA, Jin M, Yang MC, Chen CS, Bloomston M, Ostrowski MC, Hart PA, Conwell DL, Lesinski GB. Inhibition of Jak/STAT signaling reduces the activation of pancreatic stellate cells in vitro and limits caerulein-induced chronic pancreatitis in vivo. Sci Rep 2017;7:1787. [PMID: 28496202 DOI: 10.1038/s41598-017-01973-0] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
39 Komar HM, Hart PA, Cruz-Monserrate Z, Conwell DL, Lesinski GB. Local and Systemic Expression of Immunomodulatory Factors in Chronic Pancreatitis. Pancreas 2017;46:986-93. [PMID: 28796136 DOI: 10.1097/MPA.0000000000000896] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
40 Zhang Y, Yan W, Collins MA, Bednar F, Rakshit S, Zetter BR, Stanger BZ, Chung I, Rhim AD, di Magliano MP. Interleukin-6 is required for pancreatic cancer progression by promoting MAPK signaling activation and oxidative stress resistance. Cancer Res 2013;73:6359-74. [PMID: 24097820 DOI: 10.1158/0008-5472.CAN-13-1558-T] [Cited by in Crossref: 133] [Cited by in F6Publishing: 86] [Article Influence: 16.6] [Reference Citation Analysis]
41 Welsch T, Zschäbitz S, Becker V, Giese T, Bergmann F, Hinz U, Keleg S, Heller A, Sipos B, Klingmüller U, Büchler MW, Werner J, Giese NA. Prognostic significance of erythropoietin in pancreatic adenocarcinoma. PLoS One 2011;6:e23151. [PMID: 21829709 DOI: 10.1371/journal.pone.0023151] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
42 Tian G, Mi J, Wei X, Zhao D, Qiao L, Yang C, Li X, Zhang S, Li X, Wang B. Circulating interleukin-6 and cancer: A meta-analysis using Mendelian randomization. Sci Rep 2015;5:11394. [PMID: 26096712 DOI: 10.1038/srep11394] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.0] [Reference Citation Analysis]
43 Denley SM, Jamieson NB, McCall P, Oien KA, Morton JP, Carter CR, Edwards J, McKay CJ. Activation of the IL-6R/Jak/stat pathway is associated with a poor outcome in resected pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2013;17:887-898. [PMID: 23435739 DOI: 10.1007/s11605-013-2168-7] [Cited by in Crossref: 60] [Cited by in F6Publishing: 58] [Article Influence: 7.5] [Reference Citation Analysis]
44 Phillips N, Park IW, Robinson JR, Jones HP. The Perfect Storm: COVID-19 Health Disparities in US Blacks. J Racial Ethn Health Disparities 2021;8:1153-60. [PMID: 32965660 DOI: 10.1007/s40615-020-00871-y] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 15.0] [Reference Citation Analysis]
45 Cullis J, Das S, Bar-Sagi D. Kras and Tumor Immunity: Friend or Foe? Cold Spring Harb Perspect Med. 2018;8. [PMID: 29229670 DOI: 10.1101/cshperspect.a031849] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 9.7] [Reference Citation Analysis]
46 Seifert AM, List J, Heiduk M, Decker R, von Renesse J, Meinecke AC, Aust DE, Welsch T, Weitz J, Seifert L. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma. J Cancer Res Clin Oncol 2020;146:3233-40. [PMID: 32865617 DOI: 10.1007/s00432-020-03367-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
47 Shokrzadeh M, Mohammadpour A, Hoseini V, Abediankenari S, Ghassemi-barghi N, Tabari YS. SERUM CYTOKINE OF IL-2, IL-10 AND IL-12 LEVELS IN PATIENTS WITH STOMACH ADENOCARCINOMA. Arq Gastroenterol 2018;55:385-9. [DOI: 10.1590/s0004-2803.201800000-83] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
48 Hafeez BB, Jamal MS, Fischer JW, Mustafa A, Verma AK. Plumbagin, a plant derived natural agent inhibits the growth of pancreatic cancer cells in in vitro and in vivo via targeting EGFR, Stat3 and NF-κB signaling pathways. Int J Cancer 2012;131:2175-86. [PMID: 22322442 DOI: 10.1002/ijc.27478] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 5.9] [Reference Citation Analysis]
49 Wu X, Cao Y, Xiao H, Li C, Lin J. Bazedoxifene as a Novel GP130 Inhibitor for Pancreatic Cancer Therapy. Mol Cancer Ther 2016;15:2609-19. [PMID: 27535971 DOI: 10.1158/1535-7163.MCT-15-0921] [Cited by in Crossref: 39] [Cited by in F6Publishing: 26] [Article Influence: 7.8] [Reference Citation Analysis]
50 Kordes M, Larsson L, Engstrand L, Löhr JM. Pancreatic cancer cachexia: three dimensions of a complex syndrome. Br J Cancer 2021;124:1623-36. [PMID: 33742145 DOI: 10.1038/s41416-021-01301-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
51 Dai JJ, Jiang MJ, Wang XP, Tian L. Inflammation-Related Pancreatic Carcinogenesis: Mechanisms and Clinical Potentials in Advances. Pancreas 2017;46:973-85. [PMID: 28796135 DOI: 10.1097/MPA.0000000000000886] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
52 Miura T, Mitsunaga S, Ikeda M, Shimizu S, Ohno I, Takahashi H, Furuse J, Inagaki M, Higashi S, Kato H. Characterization of patients with advanced pancreatic cancer and high serum interleukin-6 levels. Pancreas. 2015;44:756-763. [PMID: 25931255 DOI: 10.1097/mpa.0000000000000335] [Cited by in Crossref: 47] [Cited by in F6Publishing: 27] [Article Influence: 9.4] [Reference Citation Analysis]
53 Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Klöppel G, Yoshimura A, Reindl W, Sipos B, Akira S, Schmid RM, Algül H. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell 2011;19:456-69. [PMID: 21481788 DOI: 10.1016/j.ccr.2011.03.009] [Cited by in Crossref: 532] [Cited by in F6Publishing: 517] [Article Influence: 53.2] [Reference Citation Analysis]
54 Hausmann S, Kong B, Michalski C, Erkan M, Friess H. The role of inflammation in pancreatic cancer. Adv Exp Med Biol. 2014;816:129-151. [PMID: 24818722 DOI: 10.1007/978-3-0348-0837-8_6] [Cited by in Crossref: 52] [Cited by in F6Publishing: 49] [Article Influence: 7.4] [Reference Citation Analysis]
55 Wu YS, Chung I, Wong WF, Masamune A, Sim MS, Looi CY. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3/Nrf2 pathway in pancreatic cancer cells. Biochim Biophys Acta Gen Subj 2017;1861:296-306. [PMID: 27750041 DOI: 10.1016/j.bbagen.2016.10.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 10.4] [Reference Citation Analysis]
56 Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H. Interleukin-6: a villain in the drama of pancreatic cancer development and progression. Hepatobiliary Pancreat Dis Int. 2014;13:371-380. [PMID: 25100121 DOI: 10.1016/s1499-3872(14)60259-9] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 9.3] [Reference Citation Analysis]
57 Vodolazkaia A, El-aalamat Y, Popovic D, Mihalyi A, Bossuyt X, Kyama CM, Fassbender A, Bokor A, Schols D, Huskens D, Meuleman C, Peeraer K, Tomassetti C, Gevaert O, Waelkens E, Kasran A, De Moor B, D'hooghe TM. Evaluation of a panel of 28 biomarkers for the non-invasive diagnosis of endometriosis. Human Reproduction 2012;27:2698-711. [DOI: 10.1093/humrep/des234] [Cited by in Crossref: 104] [Cited by in F6Publishing: 79] [Article Influence: 11.6] [Reference Citation Analysis]
58 Lorente L, Martín MM, Pérez-Cejas A, Barrios Y, Solé-Violán J, Ferreres J, Labarta L, Díaz C, Jiménez A. Association between Interleukin-6 Promoter Polymorphism (-174 G/C), Serum Interleukin-6 Levels and Mortality in Severe Septic Patients. Int J Mol Sci 2016;17:E1861. [PMID: 27834822 DOI: 10.3390/ijms17111861] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
59 Ren CZ, Hu WY, Zhang JW, Wei YY, Yu ML, Hu TJ. Establishment of inflammatory model induced by Pseudorabies virus infection in mice. J Vet Sci 2021;22:e20. [PMID: 33774936 DOI: 10.4142/jvs.2021.22.e20] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
60 Catani MV, Savini I, Tullio V, Gasperi V. The "Janus Face" of Platelets in Cancer. Int J Mol Sci. 2020;21. [PMID: 31991775 DOI: 10.3390/ijms21030788] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]